Michael S. Rosol - Sep 9, 2022 Form 4 Insider Report for NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB)

Role
Chief Medical Officer
Signature
/s/ Erika L. Eves for Michael S. Rosol, by power of attorney
Stock symbol
NAVB
Transactions as of
Sep 9, 2022
Transactions value $
$0
Form type
4
Date filed
9/13/2022, 04:07 PM
Previous filing
Jan 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NAVB Common Stock Award $0 +28.2K +193.14% $0.00 42.7K Sep 9, 2022 Direct F1, F2
transaction NAVB Common Stock Award $0 +13K +30.43% $0.00 55.7K Sep 9, 2022 Direct F2
holding NAVB Common Stock 11.3K Sep 9, 2022 Held by 401(k) Plan
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person elected to receive stock in lieu of a cash bonus. The number of shares was determined based on the closing price on the date of grant, September 9, 2022.
F2 Stock Issued under the Amended and Restated 2014 Stock Incentive Plan.